CU6 Stock Overview
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Clarity Pharmaceuticals Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$3.65 |
| 52 Week High | AU$3.76 |
| 52 Week Low | AU$0.67 |
| Beta | 1.28 |
| 1 Month Change | 37.22% |
| 3 Month Change | 50.21% |
| 1 Year Change | 393.24% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 146.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| CU6 | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 42.6% | 10.6% | 0.7% |
| 1Y | 393.2% | 43.6% | 6.3% |
Return vs Industry: CU6 exceeded the Australian Pharmaceuticals industry which returned 43.6% over the past year.
Return vs Market: CU6 exceeded the Australian Market which returned 6.3% over the past year.
Price Volatility
| CU6 volatility | |
|---|---|
| CU6 Average Weekly Movement | 9.8% |
| Pharmaceuticals Industry Average Movement | 10.2% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.4% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: CU6's share price has been volatile over the past 3 months.
Volatility Over Time: CU6's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 41 | Colin Biggin | www.claritypharmaceuticals.com |
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen.
Clarity Pharmaceuticals Ltd Fundamentals Summary
| CU6 fundamental statistics | |
|---|---|
| Market cap | AU$1.13b |
| Earnings (TTM) | -AU$30.56m |
| Revenue (TTM) | AU$9.49m |
125.1x
P/S Ratio-38.8x
P/E RatioIs CU6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CU6 income statement (TTM) | |
|---|---|
| Revenue | AU$9.49m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$9.49m |
| Other Expenses | AU$40.05m |
| Earnings | -AU$30.56m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.098 |
| Gross Margin | 100.00% |
| Net Profit Margin | -322.18% |
| Debt/Equity Ratio | 0% |
How did CU6 perform over the long term?
See historical performance and comparison